- Description
-
Bacchus Therapeutics is a biotech company that exploits cancer’s hypermetabolic state by targeting specific cancer metabolic pathways. The aberrant expression of cancer-causing gene MYC is virtually unmatched, making MYC one of the most frequently deregulated genes in human tumors, including, liver, kidney, brain, blood, breast, prostate, and lung tumors. Human studies and preclinical models have established that dysregulation of MYC underlies the pathogenesis and aggressiveness of numerous cancers.
Based on our prior research at Stanford University, we developed innovative, proprietary small molecules that target fat metabolism. This causes regression of MYC cancers in preclinical mouse and human studies and prolongs survival. Moreover, our novel metabolomic platform allows us to screen which cancers will respond to our treatment. We are able to monitor therapeutic response within a few days of treatment by measuring the actual biomarkers of our cancer therapy. This allows us to tell patients and doctors if our drug is working much faster than for standard cancer treatments.
- Number of employees
- 2 - 10 employees
- Industries
- Hospital, health, wellness & medical
Recent projects
Competitive Landscape Analysis for Bacchus Therapeutics
The main goal for the project is to build a competitive landscape for Bacchus Therapeutics and provide an analysis of the competitors in the biotech industry. This will involve understanding the current market position of Bacchus Therapeutics in relation to other companies in the biotech sector, identifying key competitors, and analyzing their strengths, weaknesses, opportunities, and threats.
Biotech Brand Identity and Website Revamp
Bacchus Therapeutics, a biotech startup, aims to revamp its existing website to better reflect its innovative approach to cancer treatment. The current website lacks a cohesive brand identity that effectively communicates the company's unique strategy of starving cancer cells of fat while sparing normal cells. The project involves crafting a comprehensive brand identity layout package, including logos and color palettes, that visually conveys this cutting-edge treatment method. The goal is to create a visually appealing and informative website that resonates with stakeholders, investors, and potential partners, enhancing the company's online presence and credibility. Key tasks include: - Analyzing the current website and identifying areas for improvement. - Designing a new logo that encapsulates the company's mission. - Developing a cohesive color palette that aligns with the brand's message. - Implementing the new brand identity into the website layout. - Ensuring the website is user-friendly and visually engaging.
Drug Development Plan for New Cancer Drug
The main goal for the project is to develop a drug development plan at the pre-IND stage in preparation for clinical trial phase 1 for a new cancer drug targeting specific cancer metabolic pathways, particularly for kidney cancer, liver cancer, and breast cancer. Additionally, the project aims to assess the potential of Bacchus' drug in getting the orphan drug indication and research the regulatory requirements for orphan drug IND.